311 related articles for article (PubMed ID: 24377754)
1. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.
Varga Z; Noske A; Ramach C; Padberg B; Moch H
BMC Cancer; 2013 Dec; 13():615. PubMed ID: 24377754
[TBL] [Abstract][Full Text] [Related]
2. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
3. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
4. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Denoux Y; Fiche M; Jacquemier J; Mathieu MC; Penault-Llorca F; Rigaud C; Roger P; Treilleux I; Vilain MO; Mathoulin-Pélissier S; Le Doussal V
Histopathology; 2003 Apr; 42(4):337-47. PubMed ID: 12653945
[TBL] [Abstract][Full Text] [Related]
5. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
7. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
McLemore LE; Albarracin CT; Gruschkus SK; Bassett RL; Wu Y; Dhamne S; Yim I; Lin K; Bedrosian I; Sneige N; Chen H
Breast Cancer Res Treat; 2021 May; 187(1):95-104. PubMed ID: 33813685
[TBL] [Abstract][Full Text] [Related]
9. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.
Wasserman BE; Carvajal-Hausdorf DE; Ho K; Wong W; Wu N; Chu VC; Lai EW; Weidler JM; Bates M; Neumeister V; Rimm DL
Lab Invest; 2017 Dec; 97(12):1521-1526. PubMed ID: 28892092
[TBL] [Abstract][Full Text] [Related]
10. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
Varga Z; Tubbs RR; Moch H
PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
13. FISH and HER2/
Patil Okaly GV; Panwar D; Lingappa KB; Kumari P; Anand A; Kumar P; Chikkalingaiah MH; Kumar RV
Indian J Cancer; 2019; 56(2):119-123. PubMed ID: 31062729
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.
Bahreini F; Soltanian AR; Mehdipour P
Breast Cancer; 2015 Nov; 22(6):615-25. PubMed ID: 24718809
[TBL] [Abstract][Full Text] [Related]
15. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
[TBL] [Abstract][Full Text] [Related]
16. HER2 Status in Gastroesophageal Adenocarcinomas: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization Methodologies.
Robertson SA; Cimino-Mathews A; Cornish TC
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):35-39. PubMed ID: 27153447
[TBL] [Abstract][Full Text] [Related]
17. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
Gown AM; Goldstein LC; Barry TS; Kussick SJ; Kandalaft PL; Kim PM; Tse CC
Mod Pathol; 2008 Oct; 21(10):1271-7. PubMed ID: 18487992
[TBL] [Abstract][Full Text] [Related]
18. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
19. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
Owens MA; Horten BC; Da Silva MM
Clin Breast Cancer; 2004 Apr; 5(1):63-9. PubMed ID: 15140287
[TBL] [Abstract][Full Text] [Related]
20. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]